Company intelligence / Profile preview

Lonza

Basel, varies, Switzerlandlonza.com ↗
Ownership
Public · LONN
Employees
~18500
Development stage
Commercial
01

Overview

Lonza does not have its own clinical pipeline but enables the development and commercial manufacturing of hundreds of client molecules. It manufactures the majority of commercially available antibody-drug conjugates globally and supports programs from preclinical through commercial supply. In recent years it has expanded capabilities in cell/gene therapies and mRNA manufacturing. In oncology alone it supported over thirty-two ADC programs in commercial or late-stage clinical supply in 2023.

Therapeutic areas
Other
Modalities
Monoclonal antibodyAntibody-drug conjugateSmall moleculemRNA-based drugsCell therapyGene therapyBiologicMicrobial therapyRecombinant protein
Industry
Contract Manufacturing Organization
02

Partnerships

Vertex Pharmaceuticals (cell therapy manufacturing facility)Multiple major biopharma partnerships for biologics/ADC/commercial drug substance manufacture—often confidential.
03

Financials

Market cap
$56.6B
Total revenue
$8B
Enterprise value
$61.1B

Beyond the preview

Go deeper on Lonza.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lonza.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call